Company: SWKH
Filing Date: 2025-04-29
Form Type: ARS
Source: 0001628280-25-020753
Chunk: 75

Company: SWK Holdings Corp
Filing Date: 2025-04-29
Form: ARS
Chunk 75
---
 assessment. The goodwill impairment test concluded that the fair value of the Company's Pharmaceutical Development reporting unit did not exceed the carrying amount and the Company recorded an impairment charge of $8.4 million . An income valuation approach was used to estimate the fair value of the Enteris reporting unit which was estimated through a probability-adjusted discounted cash flow analysis. As of December 31, 2024, certain assets of the Enteris reporting unit are classified as held for sale, including intangible assets net, of $0.2 million - see Note 7 for further details.

#### Intangible Assets
As of December 31, 2023, the gross book value, accumulated amortization, net book value and estimated useful life of acquired intangible assets were as follows (in thousands, except estimated useful life data):

|                            |     | As of December 31, 2023 |        |     |                          |        |     |                |       |     |                       |     |    |
|:---------------------------|:----|:------------------------|-------:|:----|:-------------------------|-------:|:----|:---------------|------:|:----|:----------------------|:----|---:|
|                            |     | Gross Book Value        |        |     | Accumulated Amortization |        |     | Net Book Value |       |     | Estimated Useful Life |     |    |
| License Agreement(1)       |     | $                       | 29,400 |     | $                        | 23,167 |     | $              | 6,233 |     |                       |     | 10 |
| Trade names and trademarks |     |                         |    210 |     |                          |     92 |     |                |   118 |     |                       |     | 10 |
| Customer relationships     |     |                         |    240 |     |                          |    104 |     |                |   136 |     |                       |     | 10 |
| Total                      |     | $                       | 29,850 |     | $                        | 23,363 |     | $              | 6,487 |     |                       |     |    |

(1) Prior to the Company's acquisition of Enteris, Enteris entered into the License Agreement with Cara, for oral formulation rights to Enteris’ technology to develop and commercialize Oral KORSUVA TM in any indication worldwide, excluding South Korea and Japan. Cara is obligated to